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 Multidrug-resistant tuberculosis (MDR-TB) has 
emerged as a significant global health concern1,2. There 
are alarming reports of increasing drug resistance from 
various parts of the globe which potentially threaten 
to disrupt the gains achieved in tuberculosis (TB) 
control over the last decade3. MDR-TB is essentially 
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Background & objectives: Multidrug-resistant tuberculosis (MDR-TB) has emerged as a significant 
global health concern. The most important risk factor for the development of MDR-TB is previous anti-
tuberculosis therapy. Category II pulmonary TB includes those patients who had failed previous TB 
treatment, relapsed after treatment, or defaulted during previous treatment. We carried out this study 
to ascertain the prevalence of MDR-TB among category II pulmonary TB patients.
Methods: This was a cross-sectional, descriptive study involving category II pulmonary TB patients 
diagnosed between 2005 and 2008. All sputum-positive category II TB cases were subjected to 
mycobacterial culture and drug-susceptibility testing (DST). MDR-TB was defined as TB caused by 
bacilli showing resistance to at least isoniazid and rifampicin.
Results: A total of 196 cases of sputum-positive category II pulmonary tuberculosis patients were included. 
Of these, 40 patients (20.4%) had MDR-TB. The mean age of MDR-TB patients was 33.25 ± 12.04 yr; 9 
patients (22.5%) were female. Thirty six patients showed resistance to rifampicin and isoniazid; while 4 
patients showed resistance to rifampicin, isoniazid and streptomycin. The prevalence of MDR-TB among 
category-II pulmonary tuberculosis patients was 20.4 per cent.
Interpretation & conclusions: The prevalence of MDR-TB in category II TB patients was significant. 
However, nation-wide and State-wide representative data on prevalence of MDR-TB are lacking. We 
stress the importance of continuous monitoring of drug resistance trends, in order to assess the efficacy 
of current interventions and their impact on the TB epidemic.
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a man-made phenomenon and arises due to inadequate 
treatment of drug-sensitive TB4. The prevalence of 
MDR-TB mirrors the functional state and efficacy 
of tuberculosis control programmes in the country. 
Previous treatment for TB is the strongest risk factor 
for development of MDR-TB5. Category II pulmonary 
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TB includes those patients who had failed previous TB 
treatment, relapsed after treatment, or defaulted during 
previous treatment6. Since such patients have already 
been exposed to anti-tuberculosis agents, they are at 
high risk for harbouring multi-drug resistant strains. 
Therefore, it is imperative to know the prevalence of 
MDR-TB among category II pulmonary TB patients. 
The present study focuses on the prevalence of MDR-
TB and pattern of drug resistance among category II 
pulmonary TB patients from a tertiary care centre and 
a primary care level centre in northern India.
Material & Methods
 This cross-sectional, descriptive study involved 
category II sputum positive pulmonary tuberculosis 
patients, aged 18 to 60 yr. Standard definitions for 
treatment failure, relapse and default were used6. The 
cases were recruited between March 2005 and March 
2008 through the out-patient department of All India 
Institute of Medical Sciences (AIIMS) hospital, New 
Delhi, and a dedicated chest clinic functioning at 
primary care level at Sanjay Gandhi Memorial Hospital 
in Mangolpuri, New Delhi. Data of this report were 
derived from an ongoing trial that is being done to see 
the effect of Mycobacterium w vaccination in category 
II pulmonary TB patients.
 The following patients were excluded from this 
study: (i) presence of secondary immunodeficiency 
states like HIV, organ transplantation, diabetes mellitus, 
malignancy, treatment with cytotoxic drugs currently 
or within last 3 months, use of corticosteroids; (ii) 
hepatitis B or C co-infection; (iii) alcoholism; (iv) 
extra-pulmonary TB and/or patients requiring surgical 
intervention; (v) seriously ill and moribund patients with 
very low lung reserve and BMI < 15 kg/m2 (initially 
patients were recruited with BMI <15); (vi) pregnancy 
and lactation; (vii) known seizure disorder; (viii) known 
symptomatic cardiac disease, such as arrhythmias or 
coronary artery disease; (ix) abnormal renal function 
(serum creatinine >2 mg/dl; >2+ proteinuria); (x) 
abnormal hepatic function (bilirubin > 1.5 mg/dl; AST, 
ALT, SAP more than 1.5 x ULN; PT = 1.3 x control); 
(xi) Patients with haematological abnormalities (WBC 
less than or equal to 3000/mm3; platelets less than or 
equal to 100,000/mm3). 
 The study protocol was approved by the ethics 
committee of the institute. A written informed consent 
was taken from each patient for inclusion in the 
study. All patients were subjected to sputum-smear 
microscopy for acid-fast bacillus (AFB) and chest 
radiography at the time of enrollment in category II 
treatment for the study. All sputum specimens were 
subjected to culture on Lowenstein-Jensen (L-J) slopes 
by Petroff’s method. Niacin test, catalase test and para-
nitrobenzoic acid (PNB) test were used to identify 
the isolated mycobacteria. The positive cultures were 
evaluated for drug susceptibility pattern at New Delhi 
Tuberculosis Center laboratory, New Delhi which is an 
accredited intermediate reference laboratory (IRL) for 
mycobacterial culture and drug susceptibility testing 
(DST). DST was carried out by economic variant of 1 
per cent proportion method. The sensitivity tests were 
set up with inoculum prepared from the growth of 
selected positive slopes. The standard reference strain 
H37Rv was tested in addition with each batch of tests. 
The inoculated slopes were evaluated for growth after 
28 and 42 days of incubation. DST was also carried 
out at AIIMS hospital, New Delhi. However, for this 
communication we have used data from New Delhi 
Tuberculosis Center laboratory, New Delhi as AIIMS 
hospital laboratory was under accreditation process.
Results
 A total of 445 category II pulmonary TB patients 
were screened between 2005 and 2008; 249 patients 
were excluded due to various reasons (Fig.). Finally, 
196 category II sputum positive pulmonary TB 
patients were included in the study. Their baseline 
characteristics are shown in Table I. MDR-TB was 
detected in 40 (20.4%) patients. The mean age of MDR-
TB patients was 33.25 ± 12.04 (18-55) yr with BMI of 
17.84 ± 2.4 kg/m2. Of these 40 patients, 29 (72.5%) 
had relapse, 3 (7.5 %) had treatment failure and 8 
patients (20%) were defaulters. Nine patients (22.5%) 
were female. Thirty six patients showed resistance to 
rifampicin and isoniazid; 4 patients showed resistance 
to streptomycin (in addition to rifampicin, isoniazid). 
Thus, the prevalence of MDR-TB among category-
Table I. Baseline characteristics of 196 category II pulmonary TB 
patients
Baseline characteristic Category II pulmonary TB patients 
Age (yr) 31.97 ± 10.3 (18-58)*
Sex 
Male (%)
Female (%)
146 (74.5) 
50 (25.5) 
Body mass index (kg/m2) 18.8 ± 3.9 (13.45 - 26.90)*
Relapse (%) 147 (75)
Treatment after default (%) 33 (16.8)
Treatment failure (%) 16 (8.2)
*mean ± SD (range)
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Table II. Pattern of drug resistance among category II pulmonary 
TB patients
Pattern of drug resistance Cat II patients  
No. (%)
RH 36 (18.4)
RHS 04 (2.04)
R 03 (1.5)
H 0
S 0
R, rifampicin; H, isoniazid; S, streptomycin
Table III. MDR-TB in various subcategories of Cat II pulmonary 
TB patients
Sub-category Total  
patients
MDR-TB
No. (%)
Relapse 147 29 (19.7)
Treatment after default 33 08 (24.2)
Treatment failure 16 03 (18.7)
Total 196 40 (20.4)
Table IV. Prevalence of MDR-TB among previously treated cases 
of pulmonary TB in India
Location Period of study No. of isolates MDR-TB 
(%)
Gujarat7 1983-1986 1259 30.2
Delhi8 1990-1991 81 33.3
Haryana9 1991-1995 196 49
Tamil Nadu10 1996 162 20.3
Delhi11 1996-1998 263 14
Bangalore12 1999-2000 226 12.8
Tamil Nadu† 1999-2003 440 11.8
Ahmadabad13 2000-2001 822 37
Gujarat3 2002-2007 1047 17.2
Delhi14 2006 2880 47.1
Present study 2005-2008 196 20.4
†Tuberculosis Research Centre (TRC), Chennai, unpublished data
II pulmonary tuberculosis patients was 20.4 per cent. 
The pattern of anti-tuberculosis drug resistance among 
category II pulmonary TB patients is shown in Table II. 
Prevalence of MDR-TB in various subcategories of 
category II pulmonary TB patients is shown in Table III.
Discussion
 The present study showed the prevalence of MDR-
TB among category II pulmonary TB patients as 20.4 
per cent. This was comparable to MDR-TB rates 
published in previous studies from India7-14. Studies 
conducted over the past two decades have shown 
MDR-TB rates varying from 14 to 49 per cent among 
previously treated cases (Table IV). The World Health 
Organization (WHO) fourth Global Project reported a 
MDR-TB prevalence of 17.2 per cent among previously 
treated cases in India3. 
 Our findings carry significant importance because 
there have been scarce data on the prevalence of MDR-
TB among category II pulmonary TB patients from 
the recent past. Since drug-resistance is a dynamic 
phenomenon, it is important to monitor the trend of 
drug-resistance periodically. Moreover, our study was a 
prospective study conducted over a period of three years. 
 Findings of the present study have to be interpreted 
cautiously in the light of certain limitations. First of 
all, this is a hospital-based study and hence there 
could have been significant referral bias involved in 
patient selection. Secondly, these results cannot be 
extrapolated to category II patients in other parts of 
the country. Thirdly, rigorous exclusion criteria were 
applied to screen patients, which may not be applicable 
in real-life situation. 
Fig. Flow chart showing detailed break-up of patients.
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 In conclusion, our findings showed that the 
prevalence of MDR-TB in category II TB patients 
was high and these patients are at high risk of 
amplified resistance including XDR-TB15. A large 
multi-centric study involving patients recruited at 
primary-care level from different parts of the country 
is needed to determine the nation-wide prevalence of 
MDR-TB in category II TB patients. Findings of this 
report suggest that all category II PTB patients, given 
the high prevalence of MDR-TB, should be screened 
for MDR-TB using rapid diagnostic tests (molecular 
tests) such as the line probe assays. This will facilitate 
the diagnosis of MDR-TB at an early stage and thus 
will minimize transmission of the disease16. We 
stress the importance of continuous monitoring of 
drug resistance trends, in order to assess the efficacy 
of current interventions and their impact on the TB 
epidemic.
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